CMXHF Stock Chart & Stats
$80.92
-$1.97(-2.41%)
At close: 4:00 PM EDT
$80.92
-$1.97(-2.41%)
Day’s Range― - ―
52-Week Range$63.84 - $150.82
Previous CloseN/A
Volume151.00
Average Volume (3M)1.78K
Market Cap
$45.61B
Enterprise Value$70.67K
Total Cash (Recent Filing)$1.15B
Total Debt (Recent Filing)$12.58B
Price to Earnings (P/E)36.0
Beta0.27
Next Earnings
Feb 09, 2027EPS Estimate
4.07Next Dividend Ex-DateN/A
Dividend Yield2.62%
Share Statistics
EPS (TTM)2.98
Shares Outstanding478,912,000
10 Day Avg. Volume4,226
30 Day Avg. Volume1,785
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.74
Price to Sales (P/S)3.45
P/FCF Ratio18.88
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$107.17Price Target Upside32.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)4.41
Revenue Forecast (FY)$11.09B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained operating and free cash flow supports investment in manufacturing, research and development, dividends and buybacks. This liquidity provides CSL with resilience while it addresses portfolio weakness and funds long-term growth initiatives.
Transformation SavingsSavings delivered ahead of plan can provide a durable offset to cost inflation and weaker product areas. Reinvestment of part of the benefits into commercial execution and R&D may also strengthen CSL’s longer-term growth platform.
Behring Ig And Product MomentumImmunoglobulin demand and CSL Behring’s specialty medicines underpin the company’s core biotechnology franchise. Improving Ig momentum, new product launches and plasma-network productivity support scale, market access and future revenue durability.
Bears Say
Large Impairments And Net LossThe scale of impairments signals that parts of the portfolio have materially weaker economic prospects than previously expected. The resulting loss reduced equity and returns, leaving less balance-sheet cushion and increasing execution risk.
Structural Vifor DeclineVifor’s pressure reflects durable competitive, reimbursement and regulatory challenges rather than a temporary sales fluctuation. The expected decline can weaken group growth, require portfolio remediation and reduce the contribution from CSL’s nephrology franchise.
Albumin And Group Margin PressureAlbumin pricing and market-value pressure in China can persistently weigh on product mix and profitability even if volumes stabilize. Combined with lower group gross profit, this challenges margin recovery and increases reliance on savings and higher-growth products.
CSL News
CMXHF FAQ
What was CSL’s price range in the past 12 months?
CSL lowest stock price was $63.84 and its highest was $150.82 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is $45.61B.
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Feb 09, 2027 which is in 174 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Aug 17, 2026. The company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.355 by $0.035.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of $1.62 which represents an annual dividend yield of 2.62%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 4.07.
How many shares outstanding does CSL have?
CSL has 478,912,000 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of $2.39 in its last earnings report, beating expectations of $2.355. Following the earnings report the stock price went up 15.501%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in CMXHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$107.17 (32.44% Upside)
$107.17 (32.44% Upside)
Blogger Sentiment
Bullish
CMXHF Sentiment 83%
Sector Average 61%
Sector Average 61%
Insider Transactions
Bought Shares
Worth $323.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 89%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.80%
12-Months-Change
Fundamentals
Return on Equity
2.62%
Trailing 12-Months
Asset Growth
-1.42%
Trailing 12-Months
Company Description
CSL
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
CMXHF Company Deck
CMXHF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of stabilization and operational progress (strong cash flow, ahead-of-plan transformation savings, Ig momentum in H2, successful new product launches and Seqirus share gains) but was overshadowed by very large impairments, a statutory net loss, and significant, structural headwinds in Vifor (anticipated ~25% revenue decline) plus continued pressure on albumin. While management has a clear remediation plan and delivered early positive operational signs, the scale and persistence of the portfolio and impairment issues materially weaken near-term financial prospects.View all CMXHF earnings summariesCMXHF Stock 12 Month Forecast
Average Price Target
$107.17
▲(32.44% Upside)
Technical Analysis
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Ownership Overview
0.06% Insiders
5.10% Mutual Funds
<0.01% Other Institutional Investors
84.92% Public Companies and
Individual Investors